J
Johan Vallon-Christersson
Researcher at Lund University
Publications - 99
Citations - 7444
Johan Vallon-Christersson is an academic researcher from Lund University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 38, co-authored 80 publications receiving 5956 citations. Previous affiliations of Johan Vallon-Christersson include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer
Helena Persson,Rolf Søkilde,Jari Häkkinen,Johan Vallon-Christersson,Felix Mitelman,Åke Borg,Mattias Höglund,Carlos Rovira +7 more
TL;DR: Analysis of small nucleolar RNAs (snoRNAs) that also are embedded within protein‐coding or noncoding host genes found that snoRNA hosts are selectively enriched in fusion transcripts, like miRNA host genes, and that this enrichment is associated with all sno RNA classes.
Journal ArticleDOI
Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma
Gustaf Lindgren,Lars Ekblad,Johan Vallon-Christersson,Elisabeth Kjellén,Maria Gebre-Medhin,Johan Wennerberg +5 more
TL;DR: The results suggest that the increased tumour growth during erythropoietin treatment might be due to inhibition of apoptosis, an effect that becomes significant during tissue damage such as surgery.
Journal ArticleDOI
Methylation patterns and chromatin accessibility in neuroendocrine lung cancer
Elsa Arbajian,Mattias Aine,Anna Karlsson,Johan Vallon-Christersson,Hans Brunnström,Josef Davidsson,Sofie Mohlin,Maria Planck,Johan Staaf +8 more
TL;DR: A large catalogue of gene regulatory elements related to the NE phenotype of lung cancer is identified using multilevel genomic analyses of both tumor bulk tissue and lung cancer cell lines.
Proceedings ArticleDOI
Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. A retrospective, comprehensive survey of neo-adjuvant treated HER2-positve breast cancer in the SCAN-B project 2010-2017
Martin Malmberg,Christer Larsson,Johan Vallon-Christersson,Anna Ehinger,Cecilia Hegardt,Fredrika Killander,Lisa Rydén,Lao H. Saal,Niklas Loman,Åke Borg +9 more
TL;DR: This retrospective analysis of neoadjuvant treated HER2-positive breast cancer patients shows a gradual increase of neoadedjuvant treatment and a very fast implementation of pertuzumab when it became available in Sweden.
Journal ArticleDOI
Subtype and cell type specific expression of lncRNAs provide insight into breast cancer
Sunniva Maria Stordal Bjørklund,Miriam Ragle Aure,Jari Häkkinen,Johan Vallon-Christersson,Surendra Kumar,Katrine Bull Evensen,Thomas Fleischer,Jörg Tost,Tone Frost Bathen,Elin Borgen,Anne Lise Børresen-Dale,Olav Engebraaten,Britt Fritzman,Olaf Johan Hartmann-Johnsen,Øystein Garred,Jürgen Geisler,Gry Geitvik,Solveig Hofvind,Rolf Kåresen,Anita Langerød,Ole Christian Lingjærde,Gunhild Mari Mælandsmo,Bjørn Naume,Hege G. Russnes,Torill Sauer,Helle Skjerven,Ellen Schlichting,Therese Sørlie,Kristine Kleivi Sahlberg,Anthony Mathelier,Gyan Bhanot,Shridar Ganesan,Xavier Tekpli,Vessela N. Kristensen +33 more
TL;DR: Wang et al. as mentioned in this paper reported robust associations between long non-coding RNAs (lncRNAs) expression and breast cancer clinicopathological features in two population-based cohorts: SCAN-B and TCGA.